BRIEF-Larimar Reports Positive Long-Term Data, Updates Nomlabofusp Program for Friedreich’s Ataxia

Reuters
Sep 29
BRIEF-Larimar Reports Positive Long-Term Data, Updates Nomlabofusp Program for Friedreich’s Ataxia

Sept 29 (Reuters) - Larimar Therapeutics Inc LRMR.O:

  • LARIMAR THERAPEUTICS ANNOUNCES POSITIVE DATA FROM ONGOING LONG-TERM OPEN LABEL STUDY AND UPDATES TO NOMLABOFUSP PROGRAM FOR FRIEDREICH’S ATAXIA

  • LARIMAR THERAPEUTICS INC - BLA SUBMISSION FOR ACCELERATED APPROVAL TARGETED IN Q2 2026

Source text: ID:nGNX79FfMj

Further company coverage: LRMR.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10